MedPath

Comprehensive Assessment of Risks for Miscarriage.

Recruiting
Conditions
Spontaneous Abortion
Interventions
Diagnostic Test: Markers of ultrasound
Diagnostic Test: Immunologic factors
Diagnostic Test: Serum factors
Registration Number
NCT04456660
Lead Sponsor
Orthogyn Medical Center, Bulgaria
Brief Summary

This study aims to determine the role of serum biomarkers and placental bloodflow in the comprehensive evaluation of the risk for spontaneous abortion

Detailed Description

To study the added value (if any) of combining serum markers, immunologic factors, and ultrasound parameters in comprehensively evaluating the risk for spontaneous abortion.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • visualized fetal structures in utero & heart pulsations until 8th week of gestation
  • normal THS/T4 levels
  • no uterine malformations
  • BMI < 27
  • signed informed consent
Exclusion Criteria
  • fetal structures in utero & heart pulsations not visualized until the 8th week of gestation
  • elevated THS/T4 levels
  • uterine malformations
  • BMI > 27

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
sFlt-1, Doppler and NK cells types groupImmunologic factorsMonitoring of pregnancy, including data on: * maternal age and other demographic characteristics; * ultrasound measurement of fetal heart rate (FHR) and crown-rump length (CRL), uterine arteries PI, and other parameters; * measurement of serum sFlt-1, PLGF, and glycodelin-A levels, as well as other parameters; * measurement of CD16+, CD56+, and other subpopulations of NK cells;
sFlt-1, Doppler and NK cells types groupSerum factorsMonitoring of pregnancy, including data on: * maternal age and other demographic characteristics; * ultrasound measurement of fetal heart rate (FHR) and crown-rump length (CRL), uterine arteries PI, and other parameters; * measurement of serum sFlt-1, PLGF, and glycodelin-A levels, as well as other parameters; * measurement of CD16+, CD56+, and other subpopulations of NK cells;
sFlt-1, Doppler and NK cells types groupMarkers of ultrasoundMonitoring of pregnancy, including data on: * maternal age and other demographic characteristics; * ultrasound measurement of fetal heart rate (FHR) and crown-rump length (CRL), uterine arteries PI, and other parameters; * measurement of serum sFlt-1, PLGF, and glycodelin-A levels, as well as other parameters; * measurement of CD16+, CD56+, and other subpopulations of NK cells;
Primary Outcome Measures
NameTimeMethod
Occurence of a spontaneous abortionUp to 24 weeks of gestation

Absent heart rate pulsations on an ultrasound scan

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Orthogyn Medical and Dental Center

🇧🇬

Sofia, Bulgaria

© Copyright 2025. All Rights Reserved by MedPath